Cellular Biomedicine Group Announces Upcoming Presentation to Release 48-Week Data From Phase IIb Clinical Trial for Knee Osteoarthritis ReJoin® Stem Cell Therapy

Cellular Biomedicine Group Inc. CBMG ("CBMG" or the "Company"), a biomedicine firm engaged in the development of effective stem cell therapies for degenerative diseases and immunotherapies for cancer, today announced a scheduled presentation to release 48-week clinical data from the Phase IIb trial of its ReJoin® human adipose-derived mesenchymal progenitor cell (haMPC) therapy for Knee Osteoarthritis (KOA) at the 8th Annual BioTech Showcase investor conference to be held in San Francisco, CA January 11-13, 2016. Conference: 8th Annual BioTech Showcase 2016 Date: Tuesday, January 12, 2016 Time: 10:00 AM PDT Title: Alteration of Knee Osteoarthritis, ReJoin® Phase IIb One Year Follow Up Results Location: Track C - Mission II, 4th Floor, Parc 55, Union Square, 55 Cyril Magnin Street, San Francisco, CA Presenter: Wei (William) Cao, PhD, BM, Chief Executive Officer Company management will attend the conference and be available for discussions. To arrange one-to-one meetings with management, please contact vivian.chen@grayling.com. The presented data analysis will be available on the Company website following the presentation.